Role of molecular and genetic markers in breast cancer treatment decisions

Journal of Clinical Oncology

Volumn 21, Issue 23, 2003, Pages 285s-287s

  Osborne, C Kent ^a,b   Arteaga, Carlos L ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; BREAST TUMOR; CHEMISTRY; DECISION MAKING; FEMALE; GENETIC MARKER; HUMAN;

BREAST NEOPLASMS; DECISION MAKING; FEMALE; GENETIC MARKERS; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 0642307239     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.171     Document Type: Article

References (3)

1. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole (Femara) versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606, 2001
2. Jakesz R, Hausmaninger H, Kubista E, et al: Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer- Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20: 4621-4627, 2002
3. Shin I, Yakes FM, Rojo F, Shin NY, et al: PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 8: 1145-1152, 2002